Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2023-04-13 | 2023-04-13 |
| Drug Identification Number | 02332450 | 02332450 |
| Brand name | ANACIN | ANACIN |
| Common or Proper name | Anacin | Anacin |
| Company Name | PALADIN LABS INC. | PALADIN LABS INC. |
| Ingredients | CAFFEINE ACETYLSALICYLIC ACID | CAFFEINE ACETYLSALICYLIC ACID |
| Strength(s) | 32MG 325MG | 32MG 325MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 200 tablets | 200 tablets |
| ATC code | N02BA | N02BA |
| ATC description | OTHER ANALGESICS AND ANTIPYRETICS | OTHER ANALGESICS AND ANTIPYRETICS |
| Reason for discontinuation | Manufacturing issues | Manufacturing issues |
| Anticipated discontinuation date | 2023-04-15 | 2023-04-15 |
| Actual discontinuation date | ||
| Remaining supply date | ||
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |